# Progress Note 05 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Robert Peary (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EX004-SYN
- Date: 2026-03-10
- Fictional facility: St. Posthumous Health Center
- Fictional author: Thaddeus Lindgren-Okafor, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Eight-week review: blood count, methylmalonic acid, iron studies and the biopsy results. **S**

## History of present illness

Admiral Peary returns eight weeks after starting treatment. He feels close to his old self, walks a mile with his stick and has no breathlessness. The tingling has mostly gone, but the ends of his feet remain numb and he is still unsteady in the dark. He has given himself all his weekly injections. He has had no falls and no new foot wounds. The biopsies from his endoscopy show autoimmune atrophic gastritis: atrophy of the body of the stomach with intestinal metaplasia and enterochromaffin-like cell hyperplasia, a normal antrum, no Helicobacter pylori on special stains, and no neuroendocrine tumor or dysplasia. He has no indigestion and no black stools. **S**

| Element | Detail |
|---|---|
| Hemoglobin | 14.1 g/dL; MCV 91 fL |
| Response markers | Methylmalonic acid 0.26 µmol/L; homocysteine 11 |
| Iron | Ferritin 24 ng/mL; transferrin saturation 14% |
| Biopsies | Autoimmune atrophic gastritis; no neuroendocrine tumor or dysplasia |
| Feet | Numbness at the ends persists; no wounds; no falls |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy back to near normal |
| Gastrointestinal | Negative | No indigestion, black stools or weight loss |
| Neurological | Positive | Numbness at the ends of the feet; unsteady in the dark |
| Psychiatric | Negative | Mood good |

4 systems reviewed. **S**

## Current medications

- Cyanocobalamin (vitamin B12) 1,000 micrograms (1 mg/mL) intramuscular injection once a week while the nerves recover **S**
- Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet every other day on an empty stomach with a glass of orange juice **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/74 mmHg; pulse 74 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 74 kg; BMI 22.1 kg/m². All vital signs are synthetic.

Hemoglobin: 14.1 g/dL; MCV: 91 fL; RDW: 15.6% (high); White blood cells: 6.2 10*3/uL; Platelets: 248 10*3/uL; Methylmalonic acid: 0.26 umol/L; Homocysteine: 11 umol/L; LDH: 190 U/L; Total bilirubin: 0.7 mg/dL; Ferritin: 24 ng/mL (low); Iron: 52 ug/dL; TIBC: 382 ug/dL; Transferrin saturation: 14% (low). All results are synthetic.

## Change since baseline

- Hemoglobin: 8.2 g/dL (low) at baseline, 14.1 g/dL at this visit **S**
- MCV: 118 fL (high) at baseline, 91 fL at this visit **S**
- RDW: 19.6% (high) at baseline, 15.6% (high) at this visit **S**
- White blood cells: 3.4 10*3/uL (low) at baseline, 6.2 10*3/uL at this visit **S**
- Platelets: 118 10*3/uL (low) at baseline, 248 10*3/uL at this visit **S**
- Methylmalonic acid: 3.1 umol/L (high) at baseline, 0.26 umol/L at this visit **S**
- Homocysteine: 38 umol/L (high) at baseline, 11 umol/L at this visit **S**
- LDH: 1240 U/L (high) at baseline, 190 U/L at this visit **S**
- Total bilirubin: 1.9 mg/dL (high) at baseline, 0.7 mg/dL at this visit **S**
- Ferritin: 62 ng/mL at baseline, 24 ng/mL (low) at this visit **S**
- Iron: 148 ug/dL at baseline, 52 ug/dL at this visit **S**
- TIBC: 268 ug/dL at baseline, 382 ug/dL at this visit **S**
- Transferrin saturation: 55% (high) at baseline, 14% (low) at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Good color; blood pressure 128/74, pulse 74 |
| Neurological | Vibration reduced but present at the ankles; joint position sense normal; ankle jerks absent; Romberg sway without falling; Timed Up and Go 11 seconds |
| Feet | Skin intact; small callus under the right first metatarsal head; monofilament felt at 6 of 10 sites on each forefoot |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Pernicious anemia on weekly cyanocobalamin** (D51.0). Full hematologic response at eight weeks: hemoglobin 14.1 g/dL and MCV 91 fL, with methylmalonic acid and homocysteine back to normal. Vitamin B12 itself does not need rechecking. **S**
   - Continue weekly injections while the nerves are still improving.
2. **Autoimmune atrophic gastritis** (K29.40). Confirmed by biopsy, with intestinal metaplasia in the body of the stomach and no neuroendocrine tumor or dysplasia. Autoimmune gastritis carries a higher risk of type 1 gastric neuroendocrine tumors and, to a lesser degree, of gastric adenocarcinoma. The best surveillance interval is uncertain; with extensive atrophy and metaplasia, he and Dr. Lindgren-Okafor chose endoscopy every three years. **S**
   - Repeat upper endoscopy in three years, sooner for indigestion, vomiting, black stools, weight loss or new anemia.
   - TSH every year, since autoimmune thyroid disease often accompanies autoimmune gastritis.
3. **Iron deficiency** (E61.1). Ferritin has fallen from 62 to 24 ng/mL and transferrin saturation to 14% as new red cells use the iron stores, and an acid-poor stomach absorbs iron poorly. The colonoscopy and endoscopy showed no bleeding source. **S**
   - Ferrous sulfate 325 mg every other day with orange juice, apart from tea and coffee.
   - Ferritin and transferrin saturation at the fifteen-week review; intravenous iron if oral iron fails.
4. **Subacute combined degeneration** (G32.0). Steady recovery of vibration and balance; numbness at the ends of the feet persists. **S**
   - Continue physical therapy.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Symptoms: fatigue, breathlessness, exercise tolerance, sore tongue, numbness | Every visit during active treatment | Completed today | No fatigue or breathlessness; numbness at the ends of the feet |
| Laboratory | Blood count with MCV | About eight weeks after starting replacement, with earlier checks in severe anemia | Completed today | Hemoglobin 14.1 g/dL, MCV 91 fL, RDW 15.6%, white cells 6.2, platelets 248: normalized |
| Laboratory | Methylmalonic acid and homocysteine | One week to three months after starting replacement | Completed today | Methylmalonic acid 0.26 µmol/L and homocysteine 11 µmol/L, normal; LDH 190 U/L and bilirubin 0.7 mg/dL, normal |
| Laboratory | Serum vitamin B12 | Not routinely after replacement starts | Not indicated | Not rechecked once treatment is established |
| Laboratory | Iron studies (ferritin, transferrin saturation) | When the blood count recovers, and about three months into oral iron | Completed today | Ferritin 24 ng/mL, iron 52 µg/dL, TIBC 382 µg/dL, saturation 14%: iron deficiency; oral iron started |
| Medication safety | Injection plan: doses given, self-injection technique, site problems | Every visit | Completed today | All weekly self-injections given |
| Examination | Neurological examination: vibration, joint position, reflexes, Romberg, gait, cognition | At diagnosis and at follow-up visits for six weeks to three months, then until recovery levels off | Completed today | Vibration returning at the ankles; Romberg sway; ankle jerks still absent |
| Examination | Falls and gait: falls since the last visit, Timed Up and Go, home hazards | Every visit | Completed today | No falls; Timed Up and Go 11 seconds |
| Examination | Upper endoscopy with Sydney-protocol biopsies for autoimmune gastritis, neuroendocrine tumors and dysplasia | At diagnosis of pernicious anemia; then by individual risk | Completed today | Biopsies: autoimmune atrophic gastritis with intestinal metaplasia and enterochromaffin-like cell hyperplasia; no Helicobacter pylori, neuroendocrine tumor or dysplasia; surveillance every three years by shared decision |
| Laboratory | Autoimmune screening: TSH and thyroid antibodies; HbA1c | At diagnosis, then TSH yearly | Up to date | TSH 2.6, thyroid antibody negative and HbA1c 5.5% at diagnosis; TSH due in a year |
| Self-management | Feet: daily skin checks, footwear, callus and stump skin, monofilament | Every visit | Completed today | Skin intact; monofilament felt at 6 of 10 sites on each forefoot |
| Referral | Physical therapy for balance and gait | From diagnosis until balance recovers | Completed today | Twice a week; home program |

## Goal progress

- Find the cause of the anemia and the numb feet. Outcome by 2026-01-21: Pernicious anemia confirmed: intrinsic factor and parietal cell antibodies positive, gastrin high. **S**
- Normal hemoglobin and MCV within eight weeks. Outcome by 2026-03-10: Hemoglobin 8.2 to 14.1 g/dL and MCV 118 to 91 fL at eight weeks. **S**
- Recover feeling and balance in the feet and walk without falls. In progress; target 2026-10-27. **S**
- No foot wound that goes unnoticed. In progress; target 2026-10-27. **S**
- Gastric surveillance planned with him. Outcome by 2026-03-10: Endoscopy without neuroendocrine tumor or dysplasia; repeat in three years by shared decision. **S**

## Medication changes

- Started: Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet every other day on an empty stomach with a glass of orange juice **S**

## Guideline basis

- Guidelines for the diagnosis and treatment of cobalamin and folate disorders (2014), British Committee for Standards in Haematology (British Journal of Haematology 2014;166(4):496-513)
- Vitamin B12 deficiency in over 16s: diagnosis and management (NG239) (2024), National Institute for Health and Care Excellence
- AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Expert Review (2021), American Gastroenterological Association (Gastroenterology 2021;161(4):1325-1332)
- CMID: Clinical Monitoring Intelligence Database, anemia and depression, bipolar, and mood disorders monographs (2026), Aether Forge
- Guidelines on the prevention of foot ulcers in persons with diabetes (IWGDF 2023 update) (2023), International Working Group on the Diabetic Foot (Diabetes/Metabolism Research and Reviews 2024;40(3):e3651)
- Falls Prevention in Community-Dwelling Older Adults: Interventions (2024), U.S. Preventive Services Task Force

## Follow-up

- Preventive visit in two weeks. Fifteen-week review with the blood count and iron studies. Continue weekly injections. **S**
- Next scheduled visit 2026-03-24: periodic adult preventive visit. **S**
